Kennedy Would Issue Trial Diversity Guidance, But Not Necessarily Roll Back All Anti-DEI Actions

 
• By Sarah Karlin-Smith
  
Robert F. Kennedy Jr. testifying at Senate Finance Committee. Audience shown in background.
Robert F. Kennedy Jr. responded to questions on the FDA's trial diversity policies at the 29 January Senate Finance Committee hearing. (Screenshot of Senate Finance Committee Broadcast)

More from Diversity & Inclusion

More from R&D